The Latest Breaking News from MCK

Strong economic data in recent weeks has raised signals of higher-than-expected hikes in the interest rate. Given the stalling disinflationary process, the stock market could remain volatile for some time. Thus, fundamentally strong stocks Gilead Sciences (GILD), HCA Healthcare (HCA), McKesson Corp. (MCK), and LSI Industries (LYTS) could be ideal…

The Fed’s hawkish stance to tame the stubbornly high inflation and lingering recession fears has weighed significantly on investors’ sentiments. Therefore, investors could consider buying fundamentally strong stocks, UnitedHealth Group (UNH) and McKesson (MCK), which look poised to deliver solid returns irrespective of market conditions. Keep reading.

The healthcare industry is expanding, fueled by the increasing demand and advancements such as personalized medicines and telehealth. Hence, fundamentally strong healthcare stocks Abbott Laboratories (ABT), Centene (CNC), and McKesson (MCK) might be worth buying in 2023. Read more.

Renowned investor Warren Buffett’s value investing strategy has guided investors for decades. Buffett’s Berkshire Hathaway has significantly outperformed the broader market over the past six months. During periods of economic uncertainty, fundamentally sound Warren Buffett stocks Johnson & Johnson (JNJ) and McKesson Corp. (MCK) seem like no-brainer investments for solid…

Aggressive rate hikes have pressured growth stocks since last year. However, growth stocks could prove to be promising investments this year in the hopes of the Fed pulling off a “soft landing.” Therefore, it could be wise for investors to buy fundamentally strong growth stocks Salesforce, Inc. (CRM), McKesson Corp.…

Rising bond yields and a strong dollar are dampening the stock market rally. Also, experts see a significant chance of inflation rebounding. Therefore, fundamentally strong stocks, Cigna (CI), McKesson (MCK), Pilgrim’s Pride (PPC), and Global Partners (GLP), which can potentially withstand any market conditions, could be ideal investments now. Read…

In response to the inflow of favorable macro data and the Fed's moderating rate hikes, investor optimism rekindled. This might aid growth stocks to stage a solid recovery in the near term. Against this backdrop, fast-growing quality stocks McKesson Corporation (MCK) and ADT Inc. (ADT) might be solid buys for…

Mckesson Corporation (MCK) delivered better-than-expected earnings for the last quarter and updated its outlook for fiscal 2023. Wall Street analysts expect the stock to rise more than 18% in the near term. Therefore, it could be wise to buy this medical stock now. Read more….

With expanding medical needs and technological advancements, the healthcare industry’s prospects look impressive. Moreover, healthcare stocks tend to perform relatively well, irrespective of economic conditions, thanks to the inelastic demand for their products and services. Therefore, we think Nature’s Sunshine Products (NATR), Abbott Laboratories (ABT), Humana (HUM), Molina Healthcare (MOH),…

The medical industry is poised for growth this year, driven by expanding medical needs and increasing federal support. Moreover, the industry is expected to thrive in times of uncertainty due to steady demand. Thus, quality medical stocks McKesson Corp. (MCK) and Cardinal Health (CAH) could be ideal buys this year.…

Popular healthcare service provider McKesson (MCK) has delivered robust returns despite the market turbulence over the past year. Moreover, MCK’s solid fundamentals should help it to sustain its momentum. Thus, the stock might be an ideal buy for 2023. Keep reading.